89bio Announces Appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors

Rhea-AI Summary

89bio, Inc. (Nasdaq: ETNB) announced the appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors. Dr. Atkinson, with over 20 years of expertise in biopharmaceutical development and manufacturing, previously held senior roles at Vertex and Bristol Myers Squibb. CEO Rohan Palekar emphasized Atkinson’s valuable experience in optimizing manufacturing and commercializing therapies. This comes after promising data from the Phase 1b/2a study of 89bio's lead candidate, pegozafermin, targeting liver diseases like NASH and SHTG.

Positive

• Appointment of E. Morrey Atkinson adds expertise to the Board of Directors.
• Atkinson brings a strong track record in biologics development and manufacturing.
• Recent positive data from Phase 1b/2a study of pegozafermin supports future development.

Negative

• None.

SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of E. Morrey Atkinson, Ph.D., to its Board of Directors. Dr. Atkinson currently serves as Senior Vice President, Head of Commercial Manufacturing and Supply Chain of Vertex Pharmaceuticals.

“As a seasoned biopharmaceutical industry veteran with deep-rooted expertise, Morrey is a welcome addition to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Morrey brings extensive knowledge of biologic development, manufacturing, and scale-up, including direct experience with FGF-based therapies. Additionally, he has a strong track record for optimizing manufacturing and supply chain capabilities, as well as advancing and commercializing high-quality, differentiated drug candidates for patients. His strategic insights and broad operational experience will be invaluable as we execute on our ongoing clinical development program for pegozafermin.”

Dr. Atkinson added, "I am delighted to join the Board of Directors of 89bio, especially in light of the company’s recent positive data from the Phase 1b/2a study of pegozafermin. I am incredibly excited about pegozafermin’s compelling differentiated profile in NASH and SHTG, and I look forward to working towards real change for patients alongside 89bio’s exceptional team.”

Dr. Atkinson brings over 20 years of experience in biopharmaceutical development, launch, manufacturing and supply chain. Prior to his role at Vertex, Dr. Atkinson served in a number of roles at Bristol Myers Squibb, including most recently as Senior Vice President of Global Manufacturing Operations, where he helped lead the manufacturing and cell therapy integration team for Bristol Myers Squibb's $74 billion merger with Celgene. Prior to Bristol Myers Squibb, he served as Chief Scientific Officer at Cook Pharmica (now Catalent) and Head of Biologics Development & Manufacturing Sciences at Eli Lilly, where he specialized in biologics, manufacturing and development. Throughout his career, he has participated in the development, commercialization and manufacturing of multiple commercial products, including FORTEO®, TRULICITY®, TALTZ®, TRIKAFTA®, OPDIVO®, EMPLICITI®, YERVOY®, ELIQUIS® AND ORENICA®. He has also been instrumental in spearheading the building and qualification of R&D and commercial manufacturing facilities across the United States and Europe. Dr. Atkinson holds a Ph.D. from Stanford University in Biological Sciences and a B.S. from Indiana University in Biology.

About 89bio 
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, pegozafermin, is a specifically engineered glycoPEGylated analog of FGF21. Pegozafermin is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact: 
Ryan Martins 
Chief Financial Officer 
investors@89bio.com

FAQ

Who is E. Morrey Atkinson and what is his role at 89bio?

E. Morrey Atkinson, Ph.D., has been appointed to the Board of Directors of 89bio, bringing over 20 years of experience in biopharmaceutical manufacturing and development.

What qualifications does E. Morrey Atkinson bring to 89bio?

Dr. Atkinson brings extensive knowledge in biologic development, manufacturing optimization, and has held senior positions at Vertex and Bristol Myers Squibb.

What recent progress has 89bio made with its lead candidate, pegozafermin?

89bio has reported positive data from the Phase 1b/2a study of pegozafermin, which targets nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

How does the appointment of Dr. Atkinson impact 89bio's future?

His expertise in optimizing manufacturing and drug development is expected to significantly benefit 89bio's clinical development and commercialization efforts.